Jan. 22, 2014

Study Finds Malaria Drug Combo Could Help Prevent Lupus Pregnancy Complications

Results from a study that received multiple funding support from the Lupus Foundation of America's National Research Program were published recently in the American Journal of Reproductive Immunology.  Senior study author Dr. Vikki M. Abrahams, of the Yale University School of Medicine, received a 2008 Novel Pilot Project Grant, and Caroline Albert received a 2012 Gina Finzi Memorial Student Summer Fellowship to support this study.   Listen to our podcast with Dr. Abrahams for more information about the research now and see the news release issued by Yale University below.

 (January 21, 2014 - Yale University School of Medicine) By Karen N. Peart - An anti-malaria drug combination might be useful in helping to prevent pregnancy complications in women with lupus and the related disorder antiphospholipid syndrome, Yale School of Medicine researchers have found in a new study published in the American Journal of Reproductive Immunology.

Circulating antibodies called antiphospholipid antibodies are normally produced by the body to recognize and attack bacteria and other microbe. In those with lupus and/or antiphospholipid syndrome, however, these antibodies recognize and attack the body’s own proteins, putting women at high risk for recurrent pregnancy loss and late gestational complications, such as preeclampsia.

Patients with lupus or antiphospholipid syndrome are often treated with the anti-malarial drug hydroxychloroquine. While the drug can be safely continued during pregnancy, it was unknown whether it might be beneficial in preventing pregnancy complications in women with lupus and/or antiphospholipid syndrome.

In this new study, senior author Vikki M. Abrahams, associate professor in the Department of Obstetrics, Gynecology & Reproductive Sciences at Yale, and first author and Yale medical student Caroline Albert explored whether the drug could treat obstetrical antiphospholipid syndrome.

Abrahams and Albert used a lab-based system to measure the detrimental effects of antiphospholipid antibodies on human placental trophoblast cell function.

“We found that hydroxychloroquine partially reversed some, but not all, of the detrimental effects of antiphospholipid antibodies on human placental cell function,” said Abrahams. “So perhaps some form of combination therapy that includes hydroxychloroquine may be beneficial to pregnant patients with lupus and/or antiphospholipid syndrome.”

Other authors on the study include William J. Schlesinger, Chez A. Viall, Melissa J. Mulla, Jan J. Brosens, and Lawrence W. Chamley.

The study was funded by grants from the Lupus Foundation of America and the March of Dimes. Caroline Albert was supported by the 2012 Lupus Foundation of America Gina M. Finzi Memorial Student Summer Fellowship.

Source: Yale University Press Release

Study Citation: Effect of Hydroxychloroquine on Antiphospholipid Antibody-Induced Changes in First Trimester Trophoblast Function 

Caroline R. Albert, William J. Schlesinger, Chez A. Viall, Melissa J. Mulla, Jan J. Brosens, Lawrence W. Chamley and Vikki M. Abrahams

Article first published online: 11 DEC 2013 | DOI: 10.1111/aji.12184

 


Related Stories

Research News | Jun. 03, 2013

Early Use of Hydroxychloroquine May Protect Against Organ Damage in Lupus

People with lupus who were treated with hydroxychloroquine (HCQ), an anti-malarial drug, early after a diagnosis of lupus had less cumulative organ damage at three years after diagnosis than those who did not receive HCQ, according to a new analysis.

Research News | Feb. 17, 2012

Dynamics of Lupus within First Five Years of Diagnosis

The results of this study reveal differences in autoantibody profiles over time in people with lupus, with important ethnicity-related differences, and their relationship to lupus-mediated organ damage over time.